Zusammenfassung
Baldrian und Hopfen werden traditionell bei Schlafstörungen verwendet. Die Wachheit wird mit ihrer zunehmenden Dauer durch Freisetzung von körpereigenem Adenosin im fronto-basalem Cortexbereich inhibiert. Baldrian wirkt vergleichbar und unterstützt somit die Bereitschaft zum Schlaf. Die Steuerung des Schlaf-Wach-Rhythmus führt bei zeitgerechter Interaktion dazu, dass der Schlaf eintritt. Die Steuerung ist eng mit der Freisetzung des körpereigenen Melatonin verbunden. Hopfen wirkt ähnlich wie Melatonin. Somit ist die Wirksamkeit einer Kombination von Baldrian und Hopfen bei Schlafstörungen auf wissenschaftlicher Basis zu erklären.
Summary
Valerian and hops are traditionally used as sleep-inducing aids. Alertness reduces gradually with the prolongation of wakefulness through the release of endogenous adenosine in the frontal basal cortex. Valerian has an adenosine-like action and supports the readiness to fall asleep. The control of the sleep-wake rhythm induces sleep when the time-related interaction is operating properly. The control is closely related to endogenous melatonin secretion. Hops act in a similar way to melatonin. Therefore, the efficacy of a valerian and hops combination in sleep disorder can scientifically be explained.
This is a preview of subscription content, log in via an institution to check access.
References
Borbély AA, Achermann P (2000) Homeostasis of human sleep and models of sleep regulation. In: Kryger MH, Roth T, Dement WC (eds.) Principles and Practise of Sleep Medicine. WB Saunders, Philadelphia, pp. 377–390
Finelli LA, Baumann H, Borbély AA, Achermann P (2000) Dual electroencephalogram markers of human sleep homeostasis: correlation between theta activity in waking and slow wave activity in sleep. Neuroscience 101(3): 523–529
Cajochen C, Kräuchi K, Wirz-Justice (2003) Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 15: 432–437
Porkka-Heiskanen T, Alanko L, Kalinchuk A, Stenberg D (2002) Adenosine and sleep. Sleep Med Rev 6(4): 321–332
Müller CE, Schuhmacher B, Brattström A, Abourashed EA, Koetter U (2002) Interaction of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci 71: 1939–1949
Schuhmacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller CE (2002) Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptor. J Nat Prod 65: 1479–1485
Lacher SK, Mayer R, Sichardt K, Nieber K, Müller CE (2007) Interaction of valerian extracts of different polarity with adenoside receptors: identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharmacol 73(2): 248–258
Vissiennon Z, Sichardt K, Koetter U, Brattström A, Nieber K (2006) Valerian extract Ze 911 inhibits postsynaptic potentials by activation of adenosine A1 receptors in rat cortical neurons. Planta Med 72: 579–583
Brattström A, Nieber K, Sichardt K, Vissiennon Z, Koetter U (2006) Valerian extract prepared with methanol but not with ethanol or ethyl acetate inhibits the postsynaptic potentials in rat cortical neurons indicating an adenosinelike action. Planta Med 72: 1048 (P223)
Dimpfel W, Brattström A, Koetter U (2006) Central action of a fixed valerian-hops extract combination (Ze 91019) in freely moving rats. Eur J Med Res 11: 496–500
Schellenberg R, Sauer S, Abourashed EA, Koetter U, Brattström A (2004) The fixed combination of valerian and hops (Ze 91019) acts via a central adenosine mechanism. Planta Med 70: 594–597
Santos MS, Ferreira F, Cunha AP, Carvalho AP, Ribeiro CF, Macedo T (1994) Synaptosomal GABA release as influenced by valerian rot extract-involvement of the GABA carrier. Arch Pharmacodyn Ther 327: 220–231
Ortiz JG, Nieves-Natal J, Chavez P (1999) Effects of Valerian officinalis extracts on [3H] synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 24: 1373–1378
Wiener SW, Hoffman RS, Nelson LS (2003) Withdrawal symptoms after valerian cessation. J Toxicol Clin Toxicol 41: 721
Weels SR (1995) Intentional intravenous administration of a crude valerian root extract. J Toxicol Clin Toxicol 33: 542
Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S (2006) Pharmacological properties of GABA receptor containing gamma1 subunits. Mol Pharmacol 69: 640–649
Brattström A, Baburin I, Khom S, Hering S, Koetter U (2006) Valerian extract modulates GABAA-action on its receptors. Planta Med 72: 104
Trauner G, Khom S, Benedek B, Hering S, Kopp B (2006) Identification of GABAA-modulators obtained from Valeriana officinalis L. Planta Med 72: 998
Abourashed EA, Koetter U, Brattström A (2004) In vitro binding experiments with valerian, hops and their fixed combination extract (Ze 91019) to selected central nervous receptors. Phytomedicine 11: 633–638
Dietz BM, Mahady GB, Pauli GF, Farnsworth NR (2005) Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Molecular Brain Res 138(2): 191–197
Ortiz JG, Rassi N, Maldonado M, Gonzalez-Cabrera S, Ramos I (2006) Commercial valerian interactions with [3H] flunitrazepam and [3H] MK-801 binding to rat synaptic membranes. Phytotherapy Res 20(9): 794–798
Meissner O, Häberlein H (2006) Influence of xanthohumol on the binding behaviour of GABAA receptors and their lateral mobility at hippocampal neurons. Planta Med 72: 656–658
Zanoli P, Zavatti M, Rivasi M, Brusinani, Losi G, Puia G, Avallone R, Baraldi M (2007) Evidence that the betaacids fraction of hops reduces central GABAergic neurotransmission. J Ethnopharmacol 109(1): 656–661
Lee KM, Jung JS, Song DK, Kräuter M, Kim YH (1993) Effects of Humulus lupulus extract on the central nervous system in mice. Planta Med 59(Suppl): A691
Schiller H, Forster A, Vonhoff C, Hegger M, Biller A, Winterhoff H (2006) Sedating effects of Humulus lupulus L. extracts. Phytomedicine 13: 535–541
Zanoli P, Rivasi M, Zavatti M, Brusiani F, Baraldi M (2005) New insight in the neuropharmacological activity of Humulus lupulus L. J Ethnopharmacol 102: 102–106
Butterweck V, Brattstroem A, Grundmann O, Koetter U (2007) Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice. J Pharmacy Pharmacol 59: 549–552
Rodenbeck A, Simen S, Cohrs S, Jordan W, Kinkelbur J, Staedt J, Hajak G (1998) Veränderte Schlafstrukturen als Hinweis auf die GABAerge Wirkung eines Baldrian-Hopfen-Präparates bei Patienten mit psychophysiologischer Insomnie. Somnologie 2: 26–31
Füssel A, Wolf A, Brattström A (2000) Effect of a fixed valerian hop extract combination (Ze 91019) on sleep polygraphia in patients with non-organic insomnia: a pilot study. Eur J Med Res 5: 385–390
Koetter U, Schrader E, Brattström A (2006) Effects of hops on clinical efficacy of a valerian-hops-extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Planta Med 72: 977
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brattström, A. Scientific Evidence for a Fixed Extract Combination (Ze 91019) from Valerian and Hops traditionally used as a Sleep-inducing Aid. Wien Med Wochenschr 157, 367–370 (2007). https://doi.org/10.1007/s10354-007-0442-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-007-0442-6